Atopic Dermatitis Market Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; (oral, Injectable, Topical), By Therapy; (Photo Therapy, Directed Therapy), By End-Use; By Geography; Segment Forecast, 2023 - 2032

Atopic Dermatitis Market Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; (oral, Injectable, Topical), By Therapy; (Photo Therapy, Directed Therapy), By End-Use; By Geography; Segment Forecast, 2023 - 2032

The atopic dermatitis market size is expected treach USD 25.00 billion by 2032, according ta new study by Polaris Market Research. The report ""Atopic Dermatitis Market Size, Trends, Industry Analysis Report, By Drug Type; By Route of Administration; (oral, Injectable, Topical), By Therapy; (PhotTherapy, Directed Therapy), By End-Use; By Region; Segment Forecast, 2023 - 2032"" gives a detailed insight intcurrent market dynamics and provides analysis on future market growth.

Atopic dermis typically starts in childhood and can worsen as people mature. Genetic abnormality, environmental exposure, immune system dysfunction, and difficulties with skin permeability are the causes of atopic dermatitis. Seasonal allergies, cold temperatures, and low humidity are typical causes, and the severity of the sickness will define the appropriate course of therapy.

Several different treatment options are available, as there is nknown cure for the atopic dermatitis problem. There are presently more innovative eczema medicines being developed than ever, which have expanded treatment options with minor morbidity. This covers medical procedures, including corticosteroids, antibiotics, emollients, and biological therapy.

Atopic dermatitis is a lucrative market and companies are investing in research and development tdevelop new products tcapture the market. An increase in drugs entering late-stage clinical trials with positive results is expected tsupport revenue growth for large companies in the coming years.

In December 2021, according tLEO Pharma Inc., the US Food and Drug Administration (USFDA) authorized Adbry (tralokinumab-Adam) ttreat people 18 years of age and older with atopic dermatitis whose condition is not well controlled.

Conversely, allergic reactions toff-label treatments and the expiration of product patents may pose growth challenges tthe atopic dermatitis market. There are expected tbe several new opportunities that will influence the expansion of the atopic dermatitis market due tthe government's increased support for research and development and the quickening pace of technological progress.

Atopic Dermatitis Market Report Highlights

The injectable segment dominated the market due tthe increased in the use of parenteral drugs via injections.

Hospital segment having dominance in atopic dermatitis market over the forecast period because increases the number of atopic dermatitis cases and rise in the price of medication.

The largest market in 2022 was North America, which is predicted tcontinue trule the US market. In 2022, About 90% of the need for atopic dermatitis treatments in North America was anticipated tcome from the United States. For instance, according tdata from the Allergy & Asthma Network, over 91% of patients in the United States itch every day, and 15.5% of teenagers with AD express suicidal thoughts, compared t9.1% of adolescents overall.

Some of the major players operating in the global market include Galderma, Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, GlaxoSmithKline plc, Novartis AG, Bausch Health, Bayer AG, Encore Dermatology, Inc., AstraZeneca, Sanofi, Teva Pharmaceutical Industries Ltd., Regeneron Pharmaceuticals, Mylan N.V.,

Polaris Market Research has segmented the atopic dermatitis market report based on drug type, route of administration, therapy, end use, and region:

Atopic Dermatitis, by Drug Type Outlook (Revenue - USD Billion, 2019-2032)

Anti-Inflammatory agents

Antihistamines

Immunosuppressant

Interleukin Inhibitors

Topical Phosphodiesterase (PDE-4)

Antiviral Agents

Antibiotics

Atopic Dermatitis, by Route of Administration Outlook (Revenue - USD Billion, 2019-2032)

Oral

Injectable

Topical

Atopic Dermatitis, by Therapy Outlook (Revenue - USD Billion, 2019-2032)

PhotTherapy

Directed Therapy

Atopic Dermatitis, by End Use Outlook (Revenue - USD Billion, 2019-2032)

Hospitals

Research Lab

Clinics

Atopic Dermatitis, by Geography Outlook (Revenue - USD Billion, 2019-2032)

North America

U.S.

Canada

Europe

Germany

UK

France

Italy

Spain

Asia Pacific

China

India

Japan

South Korea

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

South Africa